Jun. 22 at 12:16 PM
$BWAY announced that reimbursement coverage for its SWIFT accelerated Deep TMS protocol has expanded, reaching a cumulative opportunity of more than
$57 million.
Separately, BrainsWay recently reported that more than 80% of patients treated with the SWIFT protocol remained in remission at 12 months. If confirmed in a peer-reviewed publication with transparent reporting of patient follow-up and missing data, this would represent an exceptional outcome—well above the established benchmarks for any currently available depression treatment modality. This is amazing!
